Literature DB >> 26542182

Differential uptake and cross-presentation of soluble and necrotic cell antigen by human DC subsets.

Meng-Chieh Chiang1,2, Kirsteen M Tullett1,3,4, Yoke Seng Lee1, Adi Idris1, Yitian Ding1, Kylie J McDonald1, Andrew Kassianos1,4, Ingrid M Leal Rojas1, Varinder Jeet1, Mireille H Lahoud4,5, Kristen J Radford1,2.   

Abstract

Cross-presentation is the mechanism by which exogenous Ag is processed for recognition by CD8(+) T cells. Murine CD8α(+) DCs are specialized at cross-presenting soluble and cellular Ag, but in humans this process is poorly characterized. In this study, we examined uptake and cross-presentation of soluble and cellular Ag by human blood CD141(+) DCs, the human equivalent of mouse CD8α(+) DCs, and compared them with human monocyte-derived DCs (MoDCs) and blood CD1c(+) DC subsets. MoDCs were superior in their capacity to internalize and cross-present soluble protein whereas CD141(+) DCs were more efficient at ingesting and cross-presenting cellular Ag. Whilst cross-presentation by CD1c(+) DCs and CD141(+) DCs was dependent on the proteasome, and hence cytosolic translocation, cross-presentation by MoDCs was not. Inhibition of endosomal acidification enhanced cross-presentation by CD1c(+) DCs and MoDCs but not by CD141(+) DCs. These data demonstrate that CD1c(+) DCs, CD141(+) DCs, and MoDCs are capable of cross-presentation; however, they do so via different mechanisms. Moreover, they demonstrate that human CD141(+) DCs, like their murine CD8α(+) DC counterparts, are specialized at cross-presenting cellular Ag, most likely mediated by an enhanced capacity to ingest cellular Ag combined with subtle changes in lysosomal pH during Ag processing and use of the cytosolic pathway.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Antigen processing; Cross-presentation; Human dendritic cells

Mesh:

Substances:

Year:  2015        PMID: 26542182     DOI: 10.1002/eji.201546023

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  28 in total

1.  RNF41 regulates the damage recognition receptor Clec9A and antigen cross-presentation in mouse dendritic cells.

Authors:  Kirsteen M Tullett; Peck Szee Tan; Hae-Young Park; Ralf B Schittenhelm; Nicole Michael; Rong Li; Antonia N Policheni; Emily Gruber; Cheng Huang; Alex J Fulcher; Jillian C Danne; Peter E Czabotar; Linda M Wakim; Justine D Mintern; Georg Ramm; Kristen J Radford; Irina Caminschi; Meredith O'Keeffe; Jose A Villadangos; Mark D Wright; Marnie E Blewitt; William R Heath; Ken Shortman; Anthony W Purcell; Nicos A Nicola; Jian-Guo Zhang; Mireille H Lahoud
Journal:  Elife       Date:  2020-12-02       Impact factor: 8.140

2.  Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.

Authors:  Victor A Gall; Anne V Philips; Na Qiao; Karen Clise-Dwyer; Alexander A Perakis; Mao Zhang; Guy T Clifton; Pariya Sukhumalchandra; Qing Ma; Sangeetha M Reddy; Dihua Yu; Jeffrey J Molldrem; George E Peoples; Gheath Alatrash; Elizabeth A Mittendorf
Journal:  Cancer Res       Date:  2017-08-17       Impact factor: 12.701

3.  Butyrate and retinoic acid imprint mucosal-like dendritic cell development synergistically from bone marrow cells.

Authors:  Y Qiang; J Xu; C Yan; H Jin; T Xiao; N Yan; L Zhou; H An; X Zhou; Q Shao; S Xia
Journal:  Clin Exp Immunol       Date:  2017-06-13       Impact factor: 4.330

Review 4.  The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules.

Authors:  Freidrich M Cruz; Jeff D Colbert; Elena Merino; Barry A Kriegsman; Kenneth L Rock
Journal:  Annu Rev Immunol       Date:  2017-01-11       Impact factor: 28.527

Review 5.  Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients.

Authors:  Sreekumar Balan; John Finnigan; Nina Bhardwaj
Journal:  Cancer J       Date:  2017 Mar/Apr       Impact factor: 3.360

6.  Robust temporal map of human in vitro myelopoiesis using single-cell genomics.

Authors:  Clara Alsinet; Maria Nascimento Primo; Valentina Lorenzi; Erica Bello; Iva Kelava; Carla P Jones; Roser Vilarrasa-Blasi; Carmen Sancho-Serra; Andrew J Knights; Jong-Eun Park; Beata S Wyspianska; Gosia Trynka; David F Tough; Andrew Bassett; Daniel J Gaffney; Damiana Alvarez-Errico; Roser Vento-Tormo
Journal:  Nat Commun       Date:  2022-05-24       Impact factor: 17.694

7.  Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition.

Authors:  Kirsteen M Tullett; Ingrid M Leal Rojas; Yoshihito Minoda; Peck S Tan; Jian-Guo Zhang; Corey Smith; Rajiv Khanna; Ken Shortman; Irina Caminschi; Mireille H Lahoud; Kristen J Radford
Journal:  JCI Insight       Date:  2016-05-19

8.  Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3-dioxygenase 1 with functional effects on T cell priming.

Authors:  Simone P Sittig; Jasper J P van Beek; Georgina Flórez-Grau; Jorieke Weiden; Sonja I Buschow; Mirjam C van der Net; Rianne van Slooten; Marcel M Verbeek; P Ben H Geurtz; Johannes Textor; Carl G Figdor; I Jolanda M de Vries; Gerty Schreibelt
Journal:  Eur J Immunol       Date:  2021-03-22       Impact factor: 5.532

9.  Human Blood CD1c+ Dendritic Cells Promote Th1 and Th17 Effector Function in Memory CD4+ T Cells.

Authors:  Ingrid M Leal Rojas; Wai-Hong Mok; Frances E Pearson; Yoshihito Minoda; Tony J Kenna; Ross T Barnard; Kristen J Radford
Journal:  Front Immunol       Date:  2017-08-17       Impact factor: 7.561

10.  Directed Differentiation of Human Induced Pluripotent Stem Cells into Dendritic Cells Displaying Tolerogenic Properties and Resembling the CD141+ Subset.

Authors:  Patty Sachamitr; Alison J Leishman; Timothy J Davies; Paul J Fairchild
Journal:  Front Immunol       Date:  2018-01-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.